EverHint – Dip Bounce V2 (Reclaim) – Top 10 Signals for Jun 23, 2026
10 signals (from 45 total). Healthcare leads (18). price range $6-$305. 7 with insider selling.
What This Signal Is
Production-ready dip-bounce strategy using reclaim pattern with Phase 2 market regime filters. Improved win rate from 40.42% (V1) to 50.18% (V2) with VIX and record high filters.
Entry Criteria:
- Minimum dip: 3.3% (open to intraday low)
- Minimum bounce: 1.0% from low
- Net change range: -2.0% to +0.3%
- Price above SMA(200)
- Minimum ADV: $40M
Holding period: 1-5 days | Risk level: Medium
Market Context
The sharp VIX spike of over 12% to 19.39 signals a meaningful uptick in market fear and uncertainty, creating wider intraday price swings that can both accelerate dip conditions and amplify recovery moves. For dip-bounce reclaim strategies, this elevated volatility environment is a double-edged sword — entries require tighter risk management given the potential for false reclaims, but successful bounces can generate stronger momentum as short-covering and mean-reversion flows kick in more aggressively than in calmer markets.
The divergence across major indices tells an important story about current risk appetite. The Nasdaq's steep 2.21% decline versus the Dow's near-flat performance suggests traders are rotating away from growth and high-multiple technology names toward more defensive or value-oriented positioning. This risk-off tilt means dip-bounce setups in growth-heavy sectors face headwinds, as the broader tape is not yet providing a supportive tailwind for aggressive reclaim attempts.
Healthcare's emergence as the top sector for signals aligns well with the defensive rotation implied by today's price action. Healthcare tends to attract capital during periods of uncertainty due to its relatively non-cyclical demand profile, making reclaim setups in this sector more credible than those in sectors experiencing active selling pressure. Traders should weigh the sector's defensive appeal against the overall market volatility, using the VIX level as a guide for position sizing — conditions favor smaller, more disciplined entries until broader indices stabilize.
📊 Signals (10 of 45 total)
Ranked by dip magnitude (highest first)
| # | Ticker | Company | Sector | Price | Score | Insider | MCap |
|---|---|---|---|---|---|---|---|
| 1 | LZB | La-Z-Boy Incorporated | Consumer Cyclical | $40.30 | 0.30 | — | $1.6B |
| 2 | EGP | EastGroup Properties, ... | Real Estate | $204.89 | 0.27 | — | $11.0B |
| 3 | CBU | Community Bank System,... | Financial Services | $64.58 | 0.23 | — | $3.4B |
| 4 | WMB | The Williams Companies... | Energy | $75.79 | 0.23 | — | $92.7B |
| 5 | ARDX | Ardelyx, Inc. | Healthcare | $6.18 | 0.20 | — | $1.5B |
| 6 | SLS | SELLAS Life Sciences G... | Healthcare | $9.07 | 0.19 | — | $1.3B |
| 7 | NKTR | Nektar Therapeutics | Healthcare | $66.69 | 0.19 | -$562,580 | $1.3B |
| 8 | PRAX | Praxis Precision Medic... | Healthcare | $305.37 | 0.19 | — | $6.5B |
| 9 | SRRK | Scholar Rock Holding C... | Healthcare | $51.27 | 0.19 | — | $6.1B |
| 10 | MRK | Merck & Co., Inc. | Healthcare | $119.60 | 0.18 | — | $295.4B |
Field Notes
Sector concentration: Healthcare (18), Real Estate (8), Energy (5)
Insider selling: NKTR (Nektar Therapeutics, -$562,580)
Data coverage: 24.4% insider, 0.0% congressional, 0.0% earnings, 17.8% news
Peer Analysis
PRAX (Praxis Precision Medicines, Inc.): Leads 5 peers: CRNX ($35.91), VKTX ($34.81), KYMR ($98.25), ACAD ($22.60), LGND ($279.44)
MRK (Merck & Co., Inc.): Leads 5 peers: NVO ($47.42), NVS ($153.38), ABT ($90.53), GILD ($125.05), PFE ($24.72)
WMB (The Williams Companies, Inc.): Leads 5 peers: EPD ($37.13), PBR-A ($15.25), ET ($19.22), PBR ($17.03), KMI ($32.54)
Recent Headlines
ARDX (Ardelyx, Inc.)
- Ardelyx Stock Up 70%: What to Know About This $490,000 Insider Transaction
PRAX (Praxis Precision Medicines, Inc.)
- Praxis' Seizure Drug Move Towards Faster Development After Positive Trial Results
- Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants
SRRK (Scholar Rock Holding Corporation)
- Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD
Vlad's Take
Today's signals: Strong sector concentration in Healthcare (18 signals) suggests sector-specific rotation. 7 signals showing insider selling warrant caution.
Trading tips for this strategy:
- Entry timing: Consider entering on next-day weakness or at previous day's close level
- Position sizing: Start small (1-2% of portfolio per signal)
- Stop loss: Below today's low (tight stops for mean reversion)
- Take profit: 3-5% bounce target, or previous day's high
- Time stop: Exit if no bounce in 1-3 days
👉 Risk warning: Mean reversion can fail in strong downtrends - check broader market context 👀
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
👉 This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
📢 If this added value to your research, consider liking, sharing, or subscribing. It genuinely helps.